These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28808212)

  • 1. Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers.
    Akhtar A; Xiaoyan Wang S; Ghali L; Bell C; Wen X
    J Biomed Res; 2017 Jan; 31(3):177-188. PubMed ID: 28808212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors.
    Sönksen M; Kerl K; Bunzen H
    Med Res Rev; 2022 Jan; 42(1):374-398. PubMed ID: 34309879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Advances of Nanomedicines Delivering Arsenic Trioxide for Enhanced Tumor Therapy.
    Yu M; Zhang Y; Fang M; Jehan S; Zhou W
    Pharmaceutics; 2022 Mar; 14(4):. PubMed ID: 35456577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L; Mohassel L
    Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of arsenic-metal complexes loaded nanodrugs for solid tumor therapy: A mini review.
    Fei W; Li C; Tao J; Cai X; Yao W; Ye Y; Zhang Y; Yao Y; Song Q; Li F; Zheng C
    Int J Pharm; 2020 Jun; 583():119385. PubMed ID: 32376447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Will Arsenic Trioxide Benefit Treatment of Solid Tumor by Nano- Encapsulation?
    Fu X; Li YS; Zhao J; Yu LL; Luo RG; Liang QR; Tang Q
    Mini Rev Med Chem; 2020; 20(3):239-251. PubMed ID: 31760930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silica nanovehicles endow arsenic trioxide with an ability to effectively treat cancer cells and solid tumors.
    Zhao Z; Zhang H; Chi X; Li H; Yin Z; Huang D; Wang X; Gao J
    J Mater Chem B; 2014 Oct; 2(37):6313-6323. PubMed ID: 32262148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide.
    Chen H; Ahn R; Van den Bossche J; Thompson DH; O'Halloran TV
    Mol Cancer Ther; 2009 Jul; 8(7):1955-63. PubMed ID: 19567824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.
    Sui M; Zhang Z; Zhou J
    Chin Med J (Engl); 2014; 127(19):3503-6. PubMed ID: 25269921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment in vitro and in vivo.
    Xiao X; Liu Y; Guo M; Fei W; Zheng H; Zhang R; Zhang Y; Wei Y; Zheng G; Li F
    J Biomater Appl; 2016 Jul; 31(1):23-35. PubMed ID: 27059495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research advances on effect of arsenic trioxide on tumor].
    Feng CQ; Ma WL; Zheng WL
    Ai Zheng; 2002 Dec; 21(12):1386-9. PubMed ID: 12520754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of action of arsenic trioxide.
    Miller WH; Schipper HM; Lee JS; Singer J; Waxman S
    Cancer Res; 2002 Jul; 62(14):3893-903. PubMed ID: 12124315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide: insights into its evolution to an anticancer agent.
    Hoonjan M; Jadhav V; Bhatt P
    J Biol Inorg Chem; 2018 May; 23(3):313-329. PubMed ID: 29396610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Realgar and arsenene nanomaterials as arsenic-based anticancer agents.
    Hollow SE; Johnstone TC
    Curr Opin Chem Biol; 2023 Feb; 72():102229. PubMed ID: 36413888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A facile route to core-shell nanoparticulate formation of arsenic trioxide for effective solid tumor treatment.
    Zhang Z; Liu H; Zhou H; Zhu X; Zhao Z; Chi X; Shan H; Gao J
    Nanoscale; 2016 Feb; 8(7):4373-80. PubMed ID: 26840759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
    Zhang Y; Wu S; Luo D; Zhou J; Li D
    PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
    Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
    J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocotrienols-enriched Self-nanoemulsifying Drug Delivery System Enhances the Antileukemic Activity of All-trans Retinoic Acid but not Electrocardiogram Alterations Evoked by Its Combination with Arsenic Trioxide.
    Borges GSM; Sicard P; de Mello Gomides Loures C; Evangelista FGC; Sales CC; de Paula Sabino A; Fernandes C; Ferreira LAM; Richard S
    AAPS PharmSciTech; 2023 Mar; 24(3):79. PubMed ID: 36918482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new era for an ancient drug: arsenic trioxide and Hedgehog signaling.
    Beauchamp EM; Uren A
    Vitam Horm; 2012; 88():333-54. PubMed ID: 22391311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.